Market Indices
Sector Heatmap
AGIO — Agios Pharmaceuticals, Inc.
NasdaqAgios Pharmaceuticals, Inc.
- O
- 33.25
- H
- 33.73
- L
- 32.42
- V
- 1.25M
AGIO — Latest News & Headlines
9 StoriesIs Agios Pharmaceuticals (AGIO) Undervalued On Its PYRUKYND Expansion Story? - Simply Wall Street
Is Agios Pharmaceuticals (AGIO) Undervalued On Its PYRUKYND Expansion Story? Simply Wall Street
How (AGIO) Movements Inform Risk Allocation Models - Stock Traders Daily
How (AGIO) Movements Inform Risk Allocation Models Stock Traders Daily
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Yahoo Finance
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion Yahoo Finance
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
10 Health Care Stocks Whale Activity In Today’s Session Benzinga
BofA upgrades Candel Therapeutics stock rating on prostate cancer progress By Investing.com - Investing.com UK
BofA upgrades Candel Therapeutics stock rating on prostate cancer progress By Investing.com Investing.com UK
AGIO261120C00045000 interactive stock chart | AGIO Nov 2026 45.000 call stock - Yahoo Finance UK
AGIO261120C00045000 interactive stock chart | AGIO Nov 2026 45.000 call stock Yahoo Finance UK
AGIO Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 3.12% - Balance Sheet Strength - dars.gov.et
AGIO Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 3.12% - Balance Sheet Strength dars.gov.et
Agio Paper shareholders approve auditor re-appointment for five years - scanx.trade
Agio Paper shareholders approve auditor re-appointment for five years scanx.trade
AGIO Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 3.12% - Earnings Seasonality - dars.gov.et
AGIO Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 3.12% - Earnings Seasonality dars.gov.et